title: Positive botulinum toxin type a response is a prognosticator for migraine surgery success.
abstract: BACKGROUND
  The objective of the study was to determine whether botulinum toxin type A injections can serve as a prognosticator for migraine surgery success.
  
  
  METHODS
  Patients who underwent migraine surgery from 2000 to 2010 by the senior author (B.G.) were reviewed. Patients were included if they had botulinum toxin type A injection before surgery; had completed postinjection, postsurgery Migraine Headache Questionnaires; and had at least 1-year follow-up. Outcome variables include patient demographics and Migraine Headache Index. Treatment success was defined as at least a 50 percent reduction in Migraine Headache Index.
  
  
  RESULTS
  One hundred eighty-eight patients were included; 144 reported successful migraine headache reduction after injection (success group) and 44 did not (failure group). The groups were well matched for age, migraine headache characteristics, and number of surgical sites (p > 0.05). The surgery success rate was significantly higher in the success group overall (90.3 percent versus 72.3, p = 0.003), and in patients who reported botulinum toxin type A success and subsequent same-site surgery (97.9 percent versus 71.4 percent, p < 0.0001). Botulinum toxin type A success was prognostic for surgery success at the frontal trigger site (trigger site I) (92.5 percent versus 69.2 percent, p = 0.012), the temporal trigger site (trigger site II) (95.5 percent versus 73.3 percent, p = 0.005), and the occipital trigger site (trigger site IV) (95.9 percent versus 62.5 percent, p = 0.0003). Six patients had exclusively septum or turbinate (site III) surgery, and all failed injections.
  
  
  CONCLUSIONS
  Positive botulinum toxin type A response is a significant predictor of migraine surgery success. When injections fail, nonmuscular abnormalities should be considered.
authors.affiliation: Cleveland, Ohio From the Department of Plastic Surgery, Case Western Reserve University.
authors.forename: Michelle
authors.initials: M
authors.lastname: Lee
authors.forename: Mikhal A
authors.initials: MA
authors.lastname: Monson
authors.forename: Mengyuan T
authors.initials: MT
authors.lastname: Liu
authors.forename: Deborah
authors.initials: D
authors.lastname: Reed
authors.forename: Bahman
authors.initials: B
authors.lastname: Guyuron
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000601:surgery*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011379:Prognosis; D012074:Remission Induction
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
references.citation: Menken M, Munsat TL, Toole JF. The global burden of disease study: Implications for neurology. Arch Neurol. 2000;57:418–420.
references.citation: Lipton RB, Bigal ME, Diamond M, et al.. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–349.
references.citation: Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646–657.
references.citation: Patel NV, Bigal ME, Kolodner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology 2004;63:1432–1438.
references.citation: Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Med. 2009;7:71.
references.citation: Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pagoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg. 2000;123:669–676.
references.citation: Diener HC, Dodick DW, Aurora SK, et al.. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804–814.
references.citation: Aurora SK, Dodick DW, Turkel CC, et al.. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793–803.
references.citation: Brin MF. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146–S168.
references.citation: Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg. 2005;115:1–9.
references.citation: Liu MT, Armijo BS, Guyuron B. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012;129:413–419.
references.citation: Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg. 2009;124:461–468.
references.citation: Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. Anatomy of the corrugator supercilii muscle: Part I. Corrugator topography. Plast Reconstr Surg. 2007;120:1647–1653.
references.citation: Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. The anatomy of the corrugator supercilii muscle: Part II. Supraorbital nerve branching patterns. Plast Reconstr Surg. 2008;121:233–240.
references.citation: Janis JE, Hatef DA, Ducic I, et al.. The anatomy of the greater occipital nerve: Part II. Compression point topography. Plast Reconstr Surg. 2010;126:1563–1572.
references.citation: Janis JE, Hatef DA, Thakar H, et al.. The zygomaticotemporal branch of the trigeminal nerve: Part II. Anatomical variations. Plast Reconstr Surg. 2010;126:435–442.
references.citation: Totonchi A, Pashmini N, Guyuron B. The zygomaticotemporal branch of the trigeminal nerve: An anatomical study. Plast Reconstr Surg. 2005;115:273–277.
references.citation: Behin F, Behin B, Bigal ME, Lipton RB. Surgical treatment of patients with refractory migraine headaches and intranasal contact points. Cephalalgia 2005;25:439–443.
references.citation: Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: Single-surgeon experience using botulinum toxin and surgical decompression. Plast Reconstr Surg. 2012;128:123–131.
references.citation: Guyuron B, Kriegler JS, Davis J, Amini SB. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2010;127:603–608.
references.citation: Larson K, Lee M, Davis J, Guyuron B. Factors contributing to migraine headache surgery failure and success. Plast Reconstr Surg. 2011;128:1069–1075.
references.citation: Chepla KJ, Oh E, Guyuron B. Clinical outcomes following supraorbital foraminotomy for treatment of frontal migraine headache. Plast Reconstr Surg. 2012;129:656e–662e.